Download PDF
CC BY 4.0 · Surg J (N Y) 2022; 08(01): e60-e64
DOI: 10.1055/s-0042-1742778
Case Report

Malignant Gastrointestinal Stromal Tumor of Rectum: A Case Report and Review of Literature

Mohan Karthikeyan 
1   Institute of Surgical Gastroenterology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India
,
Chinnusamy Kolandasamy
1   Institute of Surgical Gastroenterology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India
,
Obla L. Naganath Babu
1   Institute of Surgical Gastroenterology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal tract accounting for less than 1% of all gut tumors. GISTs occurring in the rectum are extremely rare and these usually present at an advanced stage compared with other sites.

We report a case of a middle-aged female who presented with features of anemia and subacute obstruction due to a large rectal tumor and underwent abdominoperineal resection. The histopathological examination confirmed the diagnosis of high-grade malignant GIST with multiple lymph nodal metastasis. She was started on adjuvant imatinib therapy and is on follow-up without any evidence of recurrence.

The authors conclude that GIST must be included in the differential diagnosis of a rectal tumor. Diagnosis is established by biopsy and immunohistochemistry studies. Surgical resection with histological negative margins is the standard curative treatment. Adjuvant targeted therapy can reduce long-term recurrence in high-risk cases.

Keywords

gastrointestinal stromal tumor - rectum - laparoscopic resection - immunohistochemistry - high risk - imatinib


Publication History

Received: 27 November 2020

Accepted: 22 December 2021

Article published online:
16 February 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Grassi N, Cipolla C, Torcivia A. et al. Gastrointestinal stromal tumour of the rectum: report of a case and review of literature. World J Gastroenterol 2008; 14 (08) 1302-1304
    CrossrefPubMedGoogle Scholar
  • 2 DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (01) 51-58
    CrossrefPubMedGoogle Scholar
  • 3 Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100 (01) 162-168
    CrossrefPubMedGoogle Scholar
  • 4 Kalkmann J, Zeile M, Antoch G. et al; German GIST Imaging Working Group. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging 2012; 12: 126-135
    CrossrefPubMedGoogle Scholar
  • 5 Choi H, Charnsangavej C, de Castro Faria S. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183 (06) 1619-1628
    CrossrefPubMedGoogle Scholar
  • 6 Casali PG, Blay JY, Bertuzzi A. et al; ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl. 03) iii21-iii26
    CrossrefPubMedGoogle Scholar
  • 7 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): gastrointestinal stromal tumors (GISTs). Version 1.2021. Accessed January 10, 2022 at: https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations/GetFileFromFileManager?fileManagerId=11379
    PubMedGoogle Scholar
  • 8 Wong HH, Chengal R, Hardwick R. et al. Mimics of gastrointestinal stromal tumors (GISTs): implications for diagnosis and management—the Cambridge GIST study group (CGSG) experience. J Clin Oncol 2013; 31 (15, suppl): e21503-e21503
    CrossrefPubMedGoogle Scholar
  • 9 Fletcher CDM, Berman JJ, Corless C. et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33 (05) 459-465
    CrossrefPubMedGoogle Scholar
  • 10 Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13 (10) 1134-1142
    CrossrefPubMedGoogle Scholar
  • 11 Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009; 33 (09) 1401-1408
    CrossrefPubMedGoogle Scholar
  • 12 Shafizad A, Mohammadianpanah M, Nasrolahi H, Mokhtari M, Mousavi SA. Lymph node metastasis in gastrointestinal stromal tumor (GIST): to report a case. Iran J Cancer Prev 2014; 7 (03) 171-174
    PubMedGoogle Scholar
  • 13 Chen CW, Wu CC, Hsiao CW. et al. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum. Z Gastroenterol 2008; 46 (08) 760-765
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kameyama H, Kanda T, Tajima Y. et al. Management of rectal gastrointestinal stromal tumor. Transl Gastroenterol Hepatol 2018; 3: 8
    CrossrefPubMedGoogle Scholar
  • 15 Demetri GD, von Mehren M, Antonescu CR. et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 (Suppl. 02) S1-S41 , quiz S42–S44
    CrossrefPubMedGoogle Scholar
  • 16 Singhal S, Singhal A, Tugnait R. et al. Anorectal gastrointestinal stromal tumor: a case report and literature review. Case Rep Gastrointest Med 2013; 2013: 934875
    PubMedGoogle Scholar
  • 17 Joshi A. Anorectal gastrointestinal stromal tumour: a case treated with radical surgery. J Nepal Health Res Counc 2018; 16 (01) 99-101
    CrossrefPubMedGoogle Scholar
  • 18 Rivera AKU, Jabiles AG, Passiuri IC. et al. Gastrointestinal stromal tumour of the rectum and intestinal obstruction: case report. Ecancermedicalscience 2020; 14: 1139
    PubMedGoogle Scholar
  • 19 Somu K, Dashore AR, Shah AR, Anandh R. Laparoscopic excision of large lower rectal gastrointestinal stromal tumour (GIST): a case report. J Minim Access Surg 2016; 12 (03) 283-285
    CrossrefPubMedGoogle Scholar
  • 20 Nepal P, Mori S, Kita Y. et al. Management of a case of high-risk gastrointestinal stromal tumor in rectum by transanal minimal invasive surgery. World J Surg Oncol 2018; 16 (01) 165
    CrossrefPubMedGoogle Scholar
  • 21 Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23 (02) 70-83
    CrossrefPubMedGoogle Scholar
  • 22 Joensuu H, Eriksson M, Hall KS. et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 2014; 120 (15) 2325-2333
    CrossrefPubMedGoogle Scholar
  • 23 Heinrich MC, Corless CL, Demetri GD. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 (23) 4342-4349
    CrossrefPubMedGoogle Scholar
  • 24 DeMatteo RP, Ballman KV, Antonescu CR. et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 2013; 258 (03) 422-429
    CrossrefPubMedGoogle Scholar
  • 25 Joensuu H, Eriksson M, Sundby Hall K. et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307 (12) 1265-1272
    CrossrefPubMedGoogle Scholar
  • 26 Joensuu H, Eriksson M, Sundby Hall K. et al. Adjuvant imatinib for high-risk gi stromal tumor: analysis of a randomized trial. J Clin Oncol 2016; 34 (03) 244-250
    CrossrefPubMedGoogle Scholar
  • 27 Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438 (01) 1-12
    CrossrefPubMedGoogle Scholar